Role of microglia adenosine A2A receptors in retinal and brain neurodegenerative diseases

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Santiago, Ana R ^a,b,c,d   Baptista, Filipa I ^a   Santos, Paulo F ^a,c,e   Cristóvão, Gonçalo ^c   Ambrósio, António F ^a,b,c,d   Cunha, Rodrigo A ^c,d   Gomes, Catarina A ^a,c,d   Pintor, Jesús ^e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR;

ALZHEIMER DISEASE; BRAIN DEVELOPMENT; BRAIN DISEASE; CELL ACTIVATION; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DISEASE COURSE; GLAUCOMA; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; BRAIN; METABOLISM; PATHOLOGY; RETINA;

ANIMALS; BRAIN; HUMANS; MICROGLIA; NEURODEGENERATIVE DISEASES; RECEPTOR, ADENOSINE A2A; RETINA;

EID: 84921851784     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/465694     Document Type: Review

References (196)

1. K. Saijo and C. K. Glass, "Microglial cell origin and phenotypes in health and disease, " Nature Reviews Immunology, vol. 11, no. 11, pp. 775-787, 2011.
2. D. Davalos, J. Grutzendler, G. Yang et al. , "ATP mediates rapid microglial response to local brain injury in vivo, " Nature Neuroscience, vol. 8, no. 6, pp. 752-758, 2005.
3. A. Nimmerjahn, F. Kirchhoff, and F. Helmchen, "Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, " Science, vol. 308, no. 5726, pp. 1314-1318, 2005.
4. Y. Li, X. Du, C. Liu, Z. Wen, and J. Du, "Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo, " Developmental Cell, vol. 23, no. 6, pp. 1189-1202, 2012.
5. H. Wake, A. J. Moorhouse, S. Jinno, S. Kohsaka, and J. Nabekura, "Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals, " The Journal of Neuroscience, vol. 29, no. 13, pp. 3974-3980, 2009.
6. S. M. Lu, M. E. Tremblay, I. L. King et al. , "HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells, " PLoS ONE, vol. 6, no. 9, Article ID e23915, 2011.
7. A. D. Kraft, L. S. Kaltenbach, D. C. Lo, and G. J. Harry, "Activated microglia proliferate at neurites of mutant huntingtinexpressing neurons, " Neurobiology of Aging, vol. 33, no. 3, pp. 621. e17-621. e33, 2012.
8. D. Chugh, P. Nilsson, S. A. Afjei, A. Bakochi, and C. T. Ekdahl, "Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons, " Experimental Neurology, vol. 250, pp. 176-188, 2013.
9. M. Tremblay, R. L. Lowery, and A. K. Majewska, "Microglial interactions with synapses aremodulated by visual experience, " PLoS Biology, vol. 8, no. 11, Article ID e1000527, 2010.
10. R. C. Paolicelli, G. Bolasco, F. Pagani et al. , "Synaptic pruning by microglia is necessary for normal brain development, " Science, vol. 333, no. 6048, pp. 1456-1458, 2011.
11. B. Linnartz, J. Kopatz, A. J. Tenner, and H. Neumann, "Sialic acid on the neuronal glycocalyx prevents complement c1 binding and complement receptor-3-mediated removal by microglia, " The Journal of Neuroscience, vol. 32, no. 3, pp. 946-952, 2012.
12. D. P. Schafer, E. K. Lehrman, A. G. Kautzman et al. , "Microglia sculpt postnatal neural circuits in an activity and complementdependent manner, " Neuron, vol. 74, no. 4, pp. 691-705, 2012.
13. Y. Zhan, R. C. Paolicelli, F. Sforazzini et al. , "Deficient neuronmicroglia signaling results in impaired functional brain connectivity and social behavior, " Nature Neuroscience, vol. 17, no. 3, pp. 400-406, 2014.
14. A. Sierra, J. M. Encinas, J. J. P. Deudero et al. , "Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis, " Cell Stem Cell, vol. 7, no. 4, pp. 483-495, 2010.
15. J. L. Marín-Teva, I. Dusart, C. Colin, A. Gervais, N. Van Rooijen, and M. Mallat, "Microglia promote the death of developing Purkinje cell, " Neuron, vol. 41, no. 4, pp. 535-547, 2004.
16. S. Wakselman, C. Béchade, A. Roumier, D. Bernard, A. Triller, and A. Bessis, "Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor, " The Journal of Neuroscience, vol. 28, no. 32, pp. 8138-8143, 2008.
17. C. M. Tyler and L. M. Boulanger, "Complement-mediated microglial clearance of developing retinal ganglion cell axons, " Neuron, vol. 74, no. 4, pp. 597-599, 2012.
18. N. Swinnen, S. Smolders, A. Avila et al. , "Complex invasion pattern of the cerebral cortex bymicroglial cells during development of the mouse embryo, " Glia, vol. 61, no. 2, pp. 150-163, 2013.
19. C. Rigato, R. Buckinx, H. Le-Corronc, J. M. Rigo, and P. Legendre, "Pattern of invasion of the embryonicmouse spinal cord by microglial cells at the time of the onset of functional neuronal networks, " GLIA, vol. 59, no. 4, pp. 675-695, 2011.
20. C. N. Parkhurst, G. Yang, and I. Ninan, "Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor, " Cell, vol. 155, no. 7, pp. 1596-1609, 2013.
21. M. Ueno, Y. Fujita, T. Tanaka et al. , "Layer v cortical neurons require microglial support for survival during postnatal development, " Nature Neuroscience, vol. 16, no. 5, pp. 543-551, 2013.
22. S. H. Lim, E. Park, B. You et al. , "Neuronal synapse formation induced by microglia and interleukin 10, " PLoS One, vol. 8, no. 11, Article ID e81218, 2013.
23. G. Cristovao, M. J. Pinto, R. A. Cunha, R. D. Almeida, and C. A. Gomes, "Activation of microglia bolsters synapse formation, " Frontiers in Cellular Neuroscience, vol. 8, article 153, 2014.
24. D. P. Schafer, E. K. Lehrman, and B. Stevens, "The"quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS, " Glia, vol. 61, no. 1, pp. 24-36, 2013.
25. H. Kettenmann, F. Kirchhoff, and A. Verkhratsky, "Microglia: new roles for the synaptic stripper, " Neuron, vol. 77, no. 1, pp. 10-18, 2013.
26. M. E. Tremblay, B. Stevens, A. Sierra, H. Wake, A. Bessis, and A. Nimmerjahn, "The role of microglia in the healthy brain, " Journal of Neuroscience, vol. 31, no. 45, pp. 16064-16069, 2011.
27. S. Moriguchi, Y. Mizoguchi, Y. Tomimatsu et al. , "Potentiation of NMDA receptor-mediated synaptic responses by microglia, " Molecular Brain Research, vol. 119, no. 2, pp. 160-169, 2003.
28. Y. Hayashi, H. Ishibashi, K. Hashimoto, and H. Nakanishi, "Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors, " GLIA, vol. 53, no. 6, pp. 660-668, 2006.
29. J. T. Rogers, J. M. Morganti, A. D. Bachstetter et al. , "CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity, " The Journal of Neuroscience, vol. 31, no. 45, pp. 16241-16250, 2011.
30. K. Ji, J. Miyauchi, and S. E. Tsirka, "Microglia: an active player in the regulation of synaptic activity, " Neural Plasticity, vol. 2013, Article ID 627325, 9 pages, 2013.
31. K. W. Ashwell, H. Holländer, W. Streit, and J. Stone, "The appearance and distribution of microglia in the developing retina of the rat, " Visual Neuroscience, vol. 2, no. 5, pp. 437-448, 1989.
32. J. Schnitzer, "Enzyme-histochemical demonstration of microglial cells in the adult and postnatal rabbit retina, " Journal of Comparative Neurology, vol. 282, no. 2, pp. 249-263, 1989.
33. M. F. Humphrey and S. R. Moore, "Microglial responses to focal lesions of the rabbit retina: correlation with neural and macroglial reactions, " Glia, vol. 16, no. 4, pp. 325-341, 1996.
34. C. Zhang, J. K. Shen, T. T. Lam et al. , "Activation of microglia and chemokines in light-induced retinal degeneration, " Molecular Vision, vol. 11, pp. 887-895, 2005.
35. T. Harada, C. Harada, S. Kohsaka et al. , "Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration, " Journal of Neuroscience, vol. 22, no. 21, pp. 9228-9236, 2002.
36. C. Zhang, T. T. Lam, and M. O. Tso, "Heterogeneous populations of microglia/macrophages in the retina and their activation after retinal ischemia and reperfusion injury, " Experimental Eye Research, vol. 81, no. 6, pp. 700-709, 2005.
37. F. Vrabec, "Microglia in the monkey and rabbit retina, " Journal of Neuropathology and Experimental Neurology, vol. 29, no. 2, pp. 217-224, 1970.
38. B. B. Boycott and J. M. Hopkins, "Microglia in the retina of monkey and other mammals: its distinction from other types of glia and horizontal cells, " Neuroscience, vol. 6, no. 4, pp. 679-688, 1981.
39. P. L. Penfold, M. C. Madigan, and J. M. Provis, "Antibodies to human leucocyte antigens indicate subpopulations of microglia in human retina, " Visual neuroscience, vol. 7, no. 4, pp. 383-388, 1991.
40. P. Yang, P. K. Das, and A. Kijistra, "Localization and characterization of immunocompetent cells in the human retina, " Ocular Immunology and Inflammation, vol. 8, no. 3, pp. 149-157, 2000.
41. J. M. Provis, C. M. Diaz, and P. L. Penfold, "Microglia in human retina: a heterogeneous population with distinct ontogenies, " Perspectives on Developmental Neurobiology, vol. 3, no. 3, pp. 213-222, 1996.
42. D. A. Hume, V. H. Perry, and S. Gordon, "Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation in microglial cells to form a regular array in the plexiform layers, " Journal of Cell Biology, vol. 97, no. 1, pp. 253-257, 1983.
43. T. Huang, J. Cui, L. Li, P. F. Hitchcock, and Y. Li, "The role of microglia in the neurogenesis of zebrafish retina, " Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 214-220, 2012.
44. D. Checchin, F. Sennlaub, E. Levavasseur, M. Leduc, and S. Chemtob, "Potential role of microglia in retinal blood vessel formation, " Investigative Ophthalmology and Visual Science, vol. 47, no. 8, pp. 3595-3602, 2006.
45. A. M. Santos, R. Calvente, M. Tassi et al. , "Embryonic and postnatal development of microglial cells in themouse retina, " Journal of Comparative Neurology, vol. 506, no. 2, pp. 224-239, 2008.
46. C. M. Diaz-Araya, J. M. Provis, P. L. Penfold, and F. A. Billson, "Development of microglial topography in human retina, " Journal of Comparative Neurology, vol. 363, no. 1, pp. 53-68, 1995.
47. A. Ohta and M. Sitkovsky, "Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage, " Nature, vol. 414, no. 6866, pp. 916-920, 2001.
48. B. B. Fredholm, A. P. Ijzerman, K. A. Jacobson, K.-. Klotz, and J. Linden, "International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors, " Pharmacological Reviews, vol. 53, no. 4, pp. 527-552, 2001.
49. L. Luongo, F. Guida, R. Imperatore et al. , "The A1 adenosine receptor as a new player in microglia physiology, " Glia, vol. 62, no. 1, pp. 122-132, 2014.
50. M. L. Haselkorn, D. K. Shellington, E. K. Jackson et al. , "Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice, " Journal of Neurotrauma, vol. 27, no. 5, pp. 901-910, 2010.
51. D. Choi, S. Pennathur, C. Perier et al. , "Ablationof the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice, " Journal of Neuroscience, vol. 25, no. 28, pp. 6594-6600, 2005.
52. J. Y. Lee, B. S. Jhun, Y. T. Oh et al. , "Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TTNF-κα production through inhibition of PI 3-kinase/Akt and TNF-κ B activation inmurine BV2 microglial cells, " Neuroscience Letters, vol. 396, no. 1, pp. 1-6, 2006.
53. R. A. Cunha, "Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade, " Purinergic Signalling, vol. 1, no. 2, pp. 111-134, 2005.
54. C. V. Gomes, M. P. Kaster, A. R. Tomé, P. M. Agostinho, and R. A. Cunha, "Adenosine receptors and brain diseases: neuroprotection and neurodegeneration, " Biochimica et Biophysica Acta, vol. 1808, no. 5, pp. 1380-1399, 2011.
55. J. Chen, P. K. Sonsalla, F. Pedata et al. , "Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation, " Progress in Neurobiology, vol. 83, no. 5, pp. 310-331, 2007.
56. C. Gomes, R. Ferreira, J. George et al. , "Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia, " Journal of Neuroinflammation, vol. 10, article 16, 2013.
57. J. Saura, E. Angulo, A. Ejarque et al. , "Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia, " Journal ofNeurochemistry, vol. 95, no. 4, pp. 919-929, 2005.
58. A. G. Orr, A. L. Orr, X. Li, R. E. Gross, and S. F. Traynelis, "Adenosine A2A receptor mediates microglial process retraction, " Nature Neuroscience, vol. 12, no. 7, pp. 872-878, 2009.
59. S. S. Dai, Y. G. Zhou, W. Li et al. , "Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury, " The Journal of Neuroscience, vol. 30, no. 16, pp. 5802-5810, 2010.
60. J. L. Albasanz, S. Perez, M. Barrachina, I. Ferrer, and M. Martín, "Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease, " Brain Pathology, vol. 18, no. 2, pp. 211-219, 2008.
61. D. M. Holtzman, J. C. Morris, andA. M. Goate, "Alzheimer's disease: the challenge of the second century, " Science Translational Medicine, vol. 3, no. 77, Article ID77sr1, 2011.
62. L. Buée, T. Bussière, V. Buée-Scherrer, A. Delacourte, and P. R. Hof, "Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, " Brain Research Reviews, vol. 33, no. 1, pp. 95-130, 2000.
63. T. F. Gendron and L. Petrucelli, "The role of tau in neurodegeneration, " Molecular Neurodegeneration, vol. 4, no. 1, article 13, 2009.
64. D. J. Selkoe and D. Schenk, "Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics, " Annual Review of Pharmacology and Toxicology, vol. 43, pp. 545-584, 2003.
65. P. L. McGeer and E. G. McGeer, "Glial reactions in Parkinson's disease, " Movement Disorders, vol. 23, no. 4, pp. 474-483, 2008.
66. E. C. Hirsch and S. Hunot, "Neuroinflammation in Parkinson's disease: a target for neuroprotection?" The Lancet Neurology, vol. 8, no. 4, pp. 382-397, 2009.
67. T. Nagatsu and M. Sawada, "Inflammatory process in Parkinson's disease: role for cytokines, " Current Pharmaceutical Design, vol. 11, no. 8, pp. 999-1016, 2005.
68. E. Gómez-Tortosa, K. Newell, M. C. Irizarry, M. Albert, J. H. Growdon, and B. T. Hyman, "Clinical and quantitative pathologic correlates of dementia with Lewy bodies, " Neurology, vol. 53, no. 6, pp. 1284-1291, 1999.
69. E. Masliah, E. Rockenstein, I. Veinbergs et al. , "Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders, " Science, vol. 287, no. 5456, pp. 1265-1269, 2000.
70. B. A. Yankner and T. Lu, "Amyloid β-protein toxicity and the pathogenesis of Alzheimer disease, " The Journal of Biological Chemistry, vol. 284, no. 8, pp. 4755-4759, 2009.
71. P. L. McGeer, S. Itagaki, H. Tago, and E. G. McGeer, "Reactive microglia in patients with senile dementia of theAlzheimer type are positive for the histocompatibility glycoprotein HLA-DR, " Neuroscience Letters, vol. 79, no. 1-2, pp. 195-200, 1987.
72. P. L. McGeer, S. Itagaki, B. E. Boyes, andE. G. McGeer, "Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, " Neurology, vol. 38, no. 8, pp. 1285-1291, 1988.
73. S. V. More, H. Kumar, I. S. Kim, S. Y. Song, and D. K. Choi, "Cellular and molecularmediators of neuroinflammation in the pathogenesis of Parkinson's disease, "Mediators of Inflammation, vol. 2013, Article ID 952375, 12 pages, 2013.
74. X. Su, H. J. Federoff, and K. A. Maguire-Zeiss, "Mutant α-synuclein overexpression mediates early proinflammatory activity, " Neurotoxicity Research, vol. 16, no. 3, pp. 238-254, 2009.
75. Y. Ouchi, E. Yoshikawa, Y. Sekine et al. , "Microglial activation and dopamine terminal loss in early Parkinson's disease, " Annals of Neurology, vol. 57, no. 2, pp. 168-175, 2005.
76. A. Gerhard, N. Pavese, G. Hotton et al. , "In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease, " Neurobiology of Disease, vol. 21, no. 2, pp. 404-412, 2006.
77. A. Schuitemaker, M. A. Kropholler, R. Boellaard et al. , "Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study, " Neurobiology of Aging, vol. 34, no. 1, pp. 128-136, 2013.
78. A. Okello, P. Edison, H. A. Archer et al. , "Microglial activation and amyloid deposition in mild cognitive impairment: a PET study, " Neurology, vol. 72, no. 1, pp. 56-62, 2009.
79. P. Edison, H. A. Archer, A. Gerhard et al. , "Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study, " Neurobiology of Disease, vol. 32, no. 3, pp. 412-419, 2008.
80. W. Zhang, T. Wang, Z. Pei et al. , "Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease, " The FASEB Journal, vol. 19, no. 6, pp. 533-542, 2005.
81. C. K. Combs, D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth, "Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists, " Journal of Neuroscience, vol. 20, no. 2, pp. 558-567, 2000.
82. L. Qin, Y. Liu, C. Cooper, B. Liu, B. Wilson, and J. Hong, "Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species, " Journal of Neurochemistry, vol. 83, no. 4, pp. 973-983, 2002.
83. M. Ii, M. Sunamoto, K. Ohnishi, and Y. Ichimori, "β-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity, " Brain Research, vol. 720, no. 1-2, pp. 93-100, 1996.
84. L. Meda, M. A. Cassatella, G. I. Szendrei et al. , "Activation of microglial cells by β-amyloid protein and interferon-γ, " Nature, vol. 374, no. 6523, pp. 647-650, 1995.
85. M. F. McCarty, "Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders, " Medical Hypotheses, vol. 67, no. 2, pp. 251-269, 2006.
86. D. Wu, P. Teismann, K. Tieu et al. , "NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridinemodel of Parkinson's disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 6145-6150, 2003.
87. S. Hunot, F. Boissière, B. Faucheux et al. , "Nitric oxide synthase and neuronal vulnerability in Parkinson's disease, " Neuroscience, vol. 72, no. 2, pp. 355-363, 1996.
88. C. Knott, G. Stern, and G. P. Wilkin, "Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2, " Molecular and Cellular Neuroscience, vol. 16, no. 6, pp. 724-739, 2000.
89. R. LeeMosley, E. J. Benner, I. Kadiu et al. , "Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease, " Clinical Neuroscience Research, vol. 6, no. 5, pp. 261-281, 2006.
90. A. L. de Lella Ezcurra, M. Chertoff, C. Ferrari, M. Graciarena, and F. Pitossi, "Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation, " Neurobiology of Disease, vol. 37, no. 3, pp. 630-640, 2010.
91. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, "Changes in cytokines and neurotrophins in Parkinson's disease, " Journal of Neural Transmission, Supplement, no. 60, pp. 277-290, 2000.
92. P. Teismann, K. Tieu, D. K. Choi et al. , "Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5473-5478, 2003.
93. S. Hunot, M. Vila, P. Teismann et al. , "JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mousemodel of Parkinson's disease, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 665-670, 2004.
94. R. Sánchez-Pernaute, A. Ferree, O. Cooper, M. Yu, A. Brownell, and O. Isacson, "Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease, " Journal ofNeuroinflammation, vol. 1, article 6, 2004.
95. G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al. , "Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in theMPTPmodel of Parkinson disease, " Nature Medicine, vol. 5, no. 12, pp. 1403-1409, 1999.
96. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume, "Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains, " Acta Neuropathologica, vol. 106, no. 6, pp. 518-526, 2003.
97. E. Croisier, L. B. Moran, D. T. Dexter, R. K. B. Pearce, andM. B. Graeber, "Microglial inflammation in the parkinsonian substantia nigra: relationship to α-synuclein deposition, " Journal of Neuroinflammation, vol. 2, article 14, 2005.
98. D. C. Wu, V. Jackson-Lewis, M. Vila et al. , "Blockade ofmicroglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease, " Journal of Neuroscience, vol. 22, no. 5, pp. 1763-1771, 2002.
99. D. M. Paresce, H. Chung, and F. R. Maxfield, "Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglial cells, " The Journal of Biological Chemistry, vol. 272, no. 46, pp. 29390-29397, 1997.
100. D. G. Walker and L.-F. Lue, "Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases, " Journal of Neuroscience Research, vol. 81, no. 3, pp. 412-425, 2005.
101. A. Majumdar, D. Cruz, N. Asamoah et al. , "Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils, " Molecular Biology of the Cell, vol. 18, no. 4, pp. 1490-1496, 2007.
102. G. Krabbe, A. Halle, V. Matyash et al. , "Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology, " PLoS ONE, vol. 8, no. 4, Article ID e60921, 2013.
103. J. El Khoury, M. Toft, S. E. Hickman et al. , "Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease, " Nature Medicine, vol. 13, no. 4, pp. 432-438, 2007.
104. P. M. Canas, L. O. Porciúncula, G. M. A. Cunha et al. , "Adenosine A2A receptor blockade prevents synaptotoxicity andmemory dysfunction caused by β-amyloid peptides via p38mitogenactivated protein kinase pathway, " Journal of Neuroscience, vol. 29, no. 47, pp. 14741-14751, 2009.
105. N. Rebola, A. P. Simões, P. M. Canas et al. , "Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction, " Journal of Neurochemistry, vol. 117, no. 1, pp. 100-111, 2011.
106. L. Minghetti, A. Greco, R. L. Potenza et al. , "Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration, " Journal of Neuropathology and Experimental Neurology, vol. 66, no. 5, pp. 363-371, 2007.
107. F. Di Virgilio, S. Ceruti, P. Bramanti, and M. P. Abbracchio, "Purinergic signalling in inflammation of the central nervous system, " Trends in Neurosciences, vol. 32, no. 2, pp. 79-87, 2009.
108. L. Yu, H. Shen, J. E. Coelho et al. , "Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms, " Annals of Neurology, vol. 63, no. 3, pp. 338-346, 2008.
109. A. P. Simões, J. A. Duarte, F. Agasse et al. , "Blockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway, " Journal of Neuroinflammation, vol. 9, article 204, 2012.
110. T. W. Stone andW. M. H. Behan, "Interleukin-1β but not tumor necrosis factor-α potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist, " Journal of Neuroscience Research, vol. 85, no. 5, pp. 1077-1085, 2007.
111. B. B. Fredholm, J. F. Chen, R. A. Cunha, P. Svenningsson, and J. M. Vaugeois, "Adenosine and brain function, " International Review of Neurobiology, vol. 63, pp. 191-270, 2005.
112. G. W. Arendash, T. Mori, C. Cao et al. , "Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer's disease mice, " Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 661-680, 2009.
113. C. Cao, J. R. Cirrito, X. Lin et al. , "Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimerls disease transgenic mice, " Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 681-697, 2009.
114. Y. F. Chu, W. H. Chang, R. M. Black et al. , "Crude caffeine reduces memory impairment and amyloid β (1-42) levels in an Alzheimer's mouse model, " Food Chemistry, vol. 135, no. 3, pp. 2095-2102, 2012.
115. O. P. Dall'Igna, P. Fett, M. W. Gomes, D. O. Souza, R. A. Cunha, and D. R. Lara, "Caffeine and adenosine A2α receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice, " ExperimentalNeurology, vol. 203, no. 1, pp. 241-245, 2007.
116. R. A. Cunha and P. M. Agostinho, "Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline, " Journal of Alzheimer's Disease, vol. 20, supplement 1, pp. S95-S116, 2010.
117. O. P. Dall'Igna, L. O. Porciuncula, D. O. Souza, R. A. Cunha, and D. R. Lara, "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity, " British Journal of Pharmacology, vol. 138, no. 7, pp. 1207-1209, 2003.
118. H. M. Brothers, Y. Marchalant, and G. L. Wenk, "Caffeine attenuates lipopolysaccharide-induced neuroinflammation, " Neuroscience Letters, vol. 480, no. 2, pp. 97-100, 2010.
119. M. A. Lynch, "Long-termpotentiation andmemory, " Physiological Reviews, vol. 84, no. 1, pp. 87-136, 2004.
120. E. Angulo, V. Casadó, J. Mallol et al. , "A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation, " Brain Pathology, vol. 13, no. 4, pp. 440-451, 2003.
121. W. Chen, H. Wang, H. Wei, and S. Gu, "Istradefylline, an adenosineA2A receptor antagonist, for patients with Parkinson's disease: a meta-analysis, " Journal of the Neurological Sciences, vol. 324, no. 1, pp. 21-28, 2013.
122. M. Morelli, A. R. Carta, andP. Jenner, "AdenosineA2A receptors and Parkinson's disease, "Handbook of Experimental Pharmacology, vol. 193, pp. 589-615, 2009.
123. M. Pierri, E. Vaudano, T. Sager, and U. Englund, "KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse, " Neuropharmacology, vol. 48, no. 4, pp. 517-524, 2005.
124. S. Yadav, S. P. Gupta, G. Srivastava, P. K. Srivastava, and M. P. Singh, "Role of secondary mediators in caffeine-mediated neuroprotection in maneb-and paraquat-induced Parkinson's disease phenotype in the mouse, " Neurochemical Research, vol. 37, no. 4, pp. 875-884, 2012.
125. S. Stayte and B. Vissel, "Advances in non-dopaminergic treatments for Parkinson's disease, " Frontiers in Neuroscience, vol. 8, p. 113, 2014.
126. J. F. Chen, K. Xu, J. P. Petzer et al. , "Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. , " Journal of Neuroscience, vol. 21, no. 10, p. RC143, 2001.
127. M. A. Hernán, B. Takkouche, F. Caamaño-Isorna, and J. J. Gestal-Otero, "A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, " Annals of Neurology, vol. 52, no. 3, pp. 276-284, 2002.
128. J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro, "Caffeine exposure and the risk of Parkinson's disease: a systematic review andmeta-analysis of observational studiess, " Journal of Alzheimer's Disease, vol. 20, supplement 1, pp. S221-S238, 2010.
129. R. Liu, X. Guo, Y. Park et al. , "Caffeine intake, smoking, and risk of parkinson disease in men and women, " American Journal of Epidemiology, vol. 175, no. 11, pp. 1200-1207, 2012.
130. M. van der Mark, P. C. Nijssen, J. Vlaanderen et al. , "A casecontrol study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-sincecessation modifies the effect of tobacco smoking, " PLoS ONE, vol. 9, no. 4, Article ID e95297, 2014.
131. K. Sääksjärvi, P. Knekt, H. Rissanen, M. A. Laaksonen, A. Reunanen, and S. Männistö, "Prospective study of coffee consumption and risk of Parkinson's disease, " European Journal of Clinical Nutrition, vol. 62, no. 7, pp. 908-915, 2008.
132. G. W. Ross, R. D. Abbott, H. Petrovitch et al. , "Association of coffee and caffeine intake with the risk of Parkinson disease, " Journal of the American Medical Association, vol. 283, no. 20, pp. 2674-2679, 2000.
133. R. A. Popat, S. K. Van Den Eeden, C. M. Tanner et al. , "Coffee, ADORA2A, andCYP1A2: the caffeine connection in Parkinson's disease, " European Journal of Neurology, vol. 18, no. 5, pp. 756-765, 2011.
134. S. Gyoneva, L. Shapiro, C. Lazo et al. , "Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease, " Neurobiology of Disease, vol. 67, pp. 191-202, 2014.
135. World Population Ageing 2013, Department of Economic and SocialAffairs, PopulationDivision, New York, NY, USA, 2013.
136. G. Dagnelie, "Age-related psychophysical changes and low vision, " Investigative Ophthalmology & Visual Science, vol. 54, no. 14, pp. ORSF88-ORSF93, 2013.
137. S. Resnikoff, D. Pascolini, D. Etya'ale et al. , "Global data on visual impairment in the year 2002, " Bulletin of theWorldHealth Organization, vol. 82, no. 11, pp. 844-851, 2004.
138. W. Cheung, L. Guo, and M. F. Cordeiro, "Neuroprotection in glaucoma: drug-based approaches, " Optometry and Vision Science, vol. 85, no. 6, pp. E406-E416, 2008.
139. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 6th edition, 2013.
140. S. J. McKinnon, "The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma, " Investigative Ophthalmology and Visual Science, vol. 53, no. 5, pp. 2485-2487, 2012.
141. J. M. Sivak, "The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease, " Investigative Ophthalmology and Visual Science, vol. 54, no. 1, pp. 871-880, 2013.
142. G. I. Liou, J. A. Auchampach, C. J. Hillard et al. , "Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor, " Investigative Ophthalmology and Visual Science, vol. 49, no. 12, pp. 5526-5531, 2008.
143. R. J. Casson, G. Chidlow, J. P. M. Wood, J. G. Crowston, and I. Goldberg, "Definition of glaucoma: clinical and experimental concepts, " Clinical and Experimental Ophthalmology, vol. 40, no. 4, pp. 341-349, 2012.
144. T. Kersey, C. I. Clement, P. Bloom, and M. F. Cordeiro, "New trends in glaucoma risk, diagnosis & management, " Indian Journal of Medical Research, vol. 137, no. 4, pp. 659-668, 2013.
145. M. F. Cordeiro and L. A. Levin, "Clinical evidence for neuroprotection in glaucoma, " American Journal of Ophthalmology, vol. 152, no. 5, pp. 715-716, 2011.
146. G. Tezel, "The role of glia, mitochondria, and the immune system in glaucoma, " Investigative Ophthalmology and Visual Science, vol. 50, no. 3, pp. 1001-1012, 2009.
147. A. Baltmr, J. Duggan, S. Nizari, T. E. Salt, andM. F. Cordeiro, "Neuroprotection in glaucoma: is there a future role?" Experimental Eye Research, vol. 91, no. 5, pp. 554-566, 2010.
148. R. Naskar, M. Wissing, and S. Thanos, "Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma, " Investigative Ophthalmology and Visual Science, vol. 43, no. 9, pp. 2962-2968, 2002.
149. R. M. Sappington, M. Chan, and D. J. Calkins, "Interleukin-6 protects retinal ganglion cells from pressure-induced death, " Investigative Ophthalmology and Visual Science, vol. 47, no. 7, pp. 2932-2942, 2006.
150. G. Tezel, "TTNF-κ signaling in glaucomatous neurodegeneration, " Progress in Brain Research, vol. 173, pp. 409-421, 2008.
151. X. Zhou, F. Li, L. Kong, H. Tomita, C. Li, andW. Cao, "Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma, " The Journal of Biological Chemistry, vol. 280, no. 35, pp. 31240-31248, 2005.
152. A. Bosco, M. R. Steele, and M. L. Vetter, "Early microglia activation in a mouse model of chronic glaucoma, " Journal of Comparative Neurology, vol. 519, no. 4, pp. 599-620, 2011.
153. S. Taylor, C. J. Calder, J. Albon, J. T. Erichsen, M. E. Boulton, and J. E. Morgan, "Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma, " Experimental Eye Research, vol. 92, no. 5, pp. 338-343, 2011.
154. R. deHoz, B. I. Gallego, A. I. Ramirez et al. , "Rod-like microglia are restricted to eyes with laser-induced ocular hypertension but absent from the microglial changes in the contralateral untreated eye, " PLoS ONE, vol. 8, no. 12, Article IDe83733, 2013.
155. T. M. Tikka and J. E. Koistinaho, "Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia, " Journal of Immunology, vol. 166, no. 12, pp. 7527-7533, 2001.
156. A. Bosco, D. M. Inman, M. R. Steele et al. , "Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma, " Investigative Ophthalmology and Visual Science, vol. 49, no. 4, pp. 1437-1446, 2008.
157. D. S. Fong, L. P. Aiello, F. L. Ferris III, and R. Klein, "Diabetic retinopathy, " Diabetes Care, vol. 27, no. 10, pp. 2540-2553, 2004.
158. A. R. Santiago, A. J. Cristóvão, P. F. Santos, C. M. Carvalho, and A. F. Ambrósio, "High glucose induces caspase-independent cell death in retinal neural cells, " Neurobiology of Disease, vol. 25, no. 3, pp. 464-472, 2007.
159. A. J. Barber, "A new view of diabetic retinopathy: a neurodegenerative disease of the eye, " Progress in NeuroPsychopharmacology and Biological Psychiatry, vol. 27, no. 2, pp. 283-290, 2003.
160. A. J. Barber, E. Lieth, S. A. Khin, D. A. Antonetti, A. G. Buchanan, and T. W. Gardner, "Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin, " Journal of Clinical Investigation, vol. 102, no. 4, pp. 783-791, 1998.
161. A. M. A. El Asrar, D. Maimone, P. H. Morse, S. Gregory, and A. T. Reder, "Cytokines in the vitreous of patientswith proliferative diabetic retinopathy, " American Journal of Ophthalmology, vol. 114, no. 6, pp. 731-736, 1992.
162. T. Yuuki, T. Kanda, Y. Kimura et al. , "Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy, " Journal of Diabetes and Its Complications, vol. 15, no. 5, pp. 257-259, 2001.
163. J. I. Patel, G. M. Saleh, P. G. Hykin, Z. J. Gregor, and I. A. Cree, "Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy, " Eye, vol. 22, no. 2, pp. 223-228, 2008.
164. M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, and C. D. A. Stehouwer, "Markers of inflammation are crosssectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study, " Diabetologia, vol. 48, no. 2, pp. 370-378, 2005.
165. N. Demircan, B. G. Safran, M. Soylu, A. A. Ozcan, and S. Sizmaz, "Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy, " Eye, vol. 20, no. 12, pp. 1366-1369, 2006.
166. C. Gustavsson, E. Agardh, B. Bengtsson, and C. D. Agardh, "TTNF-κ is an independent serum marker for proliferative retinopathy in type 1 diabetic patients, " Journal of Diabetes and Its Complications, vol. 22, no. 5, pp. 309-316, 2008.
167. A. Carmo, J. G. Cunha-Vaz, A. P. Carvalho, andM. C. Lopes, "Larginine transport in retinas from streptozotocin diabetic rats: Correlation with the level of IL-1β and NO synthase activity, " Vision Research, vol. 39, no. 23, pp. 3817-3823, 1999.
168. R. A. Kowluru and S. Odenbach, "Role of interleukin-1β in the pathogenesis of diabetic retinopathy, " British Journal of Ophthalmology, vol. 88, no. 10, pp. 1343-1347, 2004.
169. C. Gerhardinger, M. B. Costa, M. C. Coulombe, I. Toth, T. Hoehn, and P. Grosu, "Expression of acute-phase response proteins in retinal Müller cells in diabetes, " Investigative Ophthalmology and Visual Science, vol. 46, no. 1, pp. 349-357, 2005.
170. J. K. Krady, A. Basu, C. M. Allen et al. , "Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodentmodel of diabetic retinopathy, " Diabetes, vol. 54, no. 5, pp. 1559-1565, 2005.
171. A. M. Joussen, V. Poulaki, N. Mitsiades et al. , "Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TTNF-κalpha suppression, " The FASEB Journal, vol. 16, no. 3, pp. 438-440, 2002.
172. Y. Behl, P. Krothapalli, T. Desta, A. DiPiazza, S. Roy, and D. T. Graves, "Diabetes-enhanced tumor necrosis factor-α production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy, " The American Journal of Pathology, vol. 172, no. 5, pp. 1411-1418, 2008.
173. C. Gustavsson, E. Agardh, B. Bengtsson, and C. D. Agardh, "TTNF-κ is an independent serum marker for proliferative retinopathy in type 1 diabetic patients, " Journal of Diabetes and Its Complications, vol. 44, no. 5, pp. 2184-2191, 2003.
174. E. C. Leal, A. Manivannan, K. Hosoya et al. , "Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy, " Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 5257-5265, 2007.
175. C. A. Aveleira, C. M. Lin, S. F. Abcouwer, A. F. Ambrósio, and D. A. Antonetti, "TTNF-κ signals through PKCζ/TNF-κB to alter the tight junction complex and increase retinal endothelial cell permeability, " Diabetes, vol. 59, no. 11, pp. 2872-2882, 2010.
176. G. N. Costa, J. Vindeirinho, C. Cavadas, A. F. Ambrósio, and P. F. Santos, "Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose, " Molecular and Cellular Neuroscience, vol. 50, no. 1, pp. 113-123, 2012.
177. H. Zeng, W. R. Green, andM. O. M. Tso, "Microglial activation in human diabetic retinopathy, " Archives of Ophthalmology, vol. 126, no. 2, pp. 227-232, 2008.
178. A. J. Barber, D. A. Antonetti, T. S. Kern et al. , "The Ins2Akita mouse as a model of early retinal complications in diabetes, " Investigative Ophthalmology and Visual Science, vol. 46, no. 6, pp. 2210-2218, 2005.
179. A. S. Ibrahim, A. B. El-Remessy, S. Matragoon et al. , "Retinal microglial activation and inflammation induced by amadoriglycated albumin in a rat model of diabetes, " Diabetes, vol. 60, no. 4, pp. 1122-1133, 2011.
180. X. X. Zeng, Y. K. Ng, and E. A. Ling, "Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats, " Visual Neuroscience, vol. 17, no. 3, pp. 463-471, 2000.
181. S. Omri, F. Behar-Cohen, Y. de Kozak et al. , "Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCzeta in the Goto Kakizaki ratmodel, "TheAmericanJournal of Pathology, vol. 179, no. 2, pp. 942-953, 2011.
182. N. N. Osborne, R. J. Casson, J. P. M. Wood, G. Chidlow, M. Graham, and J. Melena, "Retinal ischemia: mechanisms of damage and potential therapeutic strategies, " Progress in Retinal and Eye Research, vol. 23, no. 1, pp. 91-147, 2004.
183. T. T. Lam, A. S. Abler, andM. O. M. Tso, "Apoptosis and caspases after ischemia-reperfusion injury in rat retina, " Investigative Ophthalmology and Visual Science, vol. 40, no. 5, pp. 967-975, 1999.
184. H. A. Quigley, "Neuronal death in glaucoma, " Progress in Retinal and Eye Research, vol. 18, no. 1, pp. 39-57, 1999.
185. N. N. Osborne, J. Melena, G. Chidlow, and J. P. M. Wood, "A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma, " The British Journal of Ophthalmology, vol. 85, no. 10, pp. 1252-1259, 2001.
186. G. J. Ghiardi, J. M. Gidday, and S. Roth, "The purine nucleoside adenosine in retinal ischemia-reperfusion injury, " Vision Research, vol. 39, no. 15, pp. 2519-2535, 1999.
187. B. Li, P. S. Rosenbaum, N. M. Jennings, K. M. Maxwell, and S. Roth, "Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat, " Experimental Eye Research, vol. 68, no. 1, pp. 9-17, 1999.
188. T. Konno, A. Sato, T. Uchibori, A. Nagai, K. Kogi, and N. Nakahata, "Adenosine A2A receptor mediated protective effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on retinal ischaemia/reperfusion damage in rats, " British Journal of Ophthalmology, vol. 90, no. 7, pp. 900-905, 2006.
189. K. D. Steinsapir and R. A. Goldberg, "Traumatic optic neuropathy, " Survey of Ophthalmology, vol. 38, no. 6, pp. 487-518, 1994.
190. S. Ahmad, N. Fatteh, N. M. El-Sherbiny et al. , "Potential role of A2A adenosine receptor in traumatic optic neuropathy, " Journal of Neuroimmunology, vol. 264, no. 1-2, pp. 54-64, 2013.
191. E. Garcia-Valenzuela and S. C. Sharma, "Laminar restriction of retinalmacrophagic response toopticnerve axotomy inthe rat, " Journal of Neurobiology, vol. 40, no. 1, pp. 55-66, 1999.
192. C. Zhang andM. O. M. Tso, "Characterization of activated retinal microglia following optic axotomy, " Journal of Neuroscience Research, vol. 73, no. 6, pp. 840-845, 2003.
193. S. G. Wohl, C. W. Schmeer, O. W. Witte, and S. Isenmann, "Proliferative response of microglia and macrophages in the adult mouse eye after optic nerve lesion, " Investigative Ophthalmology and Visual Science, vol. 51, no. 5, pp. 2686-2696, 2010.
194. J. Vindeirinho, G. N. Costa, M. B. Correia, C. Cavadas, and P. F. Santos, "Effect of diabetes/hyperglycemia on the rat retinal adenosinergic system, " PLoS ONE, vol. 8, no. 6, Article ID e67499, 2013.
195. N. M. Elsherbiny, S. Ahmad, M. Naime et al. , "ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy, " Life Sciences, vol. 93, no. 2-3, pp. 78-88, 2013.
196. M. Madeira, F. Elvas, J. Martins, A. F. Ambrósio, and A. R. Santiago, "denosine A2AR blockade prevents retinal microglial activation, " in Proceedings of the 22nd IUBMB 37th FEBS Congress, Blackwell, Seville, Spain, 2012.